Turning a Collagenesis-Inducing Peptide Into a Potent Antibacterial and Antibiofilm Agent Against Multidrug-Resistant Gram-Negative Bacteria by Gomes, Ana et al.
fmicb-10-01915 August 17, 2019 Time: 15:42 # 1
ORIGINAL RESEARCH
published: 20 August 2019
doi: 10.3389/fmicb.2019.01915
Edited by:
Kai Hilpert,
St George’s, University of London,
United Kingdom
Reviewed by:
Mukesh Pasupuleti,
SRM Institute of Science
and Technology, India
Octavio Luiz Franco,
Universidade Católica de Brasília,
Brazil
Artur Schmidtchen,
Lund University, Sweden
*Correspondence:
Paula Gomes
pgomes@fc.up.pt
Specialty section:
This article was submitted to
Antimicrobials, Resistance and
Chemotherapy,
a section of the journal
Frontiers in Microbiology
Received: 19 June 2019
Accepted: 05 August 2019
Published: 20 August 2019
Citation:
Gomes A, Bessa LJ, Fernandes I,
Ferraz R, Mateus N, Gameiro P,
Teixeira C and Gomes P (2019)
Turning a Collagenesis-Inducing
Peptide Into a Potent Antibacterial
and Antibiofilm Agent Against
Multidrug-Resistant Gram-Negative
Bacteria. Front. Microbiol. 10:1915.
doi: 10.3389/fmicb.2019.01915
Turning a Collagenesis-Inducing
Peptide Into a Potent Antibacterial
and Antibiofilm Agent Against
Multidrug-Resistant Gram-Negative
Bacteria
Ana Gomes1, Lucinda J. Bessa1, Iva Fernandes1, Ricardo Ferraz1,2, Nuno Mateus1,
Paula Gameiro1, Cátia Teixeira1 and Paula Gomes1*
1 Laboratório Associado para a Química Verde da Rede de Química e Tecnologia (LAQV-REQUIMTE), Departamento
de Química e Bioquímica, Faculdade de Ciências, Universidade do Porto, Porto, Portugal, 2 Ciências Químicas e das
Biomoléculas, Escola Superior de Saúde, Politécnico do Porto, Porto, Portugal
Antimicrobial resistance is becoming one the most serious health threats worldwide, as it
not only hampers effective treatment of infectious diseases using current antibiotics,
but also increases the risks of medical procedures like surgery, transplantation, bone
and dental implantation, chemotherapy, or chronic wound management. To date,
there are no effective measures to tackle life-threatening nosocomial infections caused
by multidrug resistant bacterial species, of which Gram-negative species within the
so-called “ESKAPE” pathogens are the most worrisome. Many such bacteria are
frequently isolated from severely infected skin lesions such as diabetic foot ulcers
(DFU). In this connection, we are pursuing new peptide constructs encompassing
antimicrobial and collagenesis-inducing motifs, to tackle skin and soft tissue infections
by exerting a dual effect: antimicrobial protection and faster healing of the wound. This
produced peptide 3.1-PP4 showed MIC values as low as 1.0 and 2.1 µM against
Escherichia coli and Pseudomonas aeruginosa, respectively, and low toxicity to HFF-1
human fibroblasts. Remarkably, the peptide was also potent against multidrug-resistant
isolates of Klebsiella pneumoniae, E. coli, and P. aeruginosa (MIC values between
0.5 and 4.1 µM), and hampered the formation of/disaggregated K. pneumoniae
biofilms of resistant clinical isolates. Moreover, this notable hybrid peptide retained
the collagenesis-inducing behavior of the reference cosmeceutical peptide C16-PP4
(“Matrixyl”). In conclusion, 3.1-PP4 is a highly promising lead toward development of
a topical treatment for severely infected skin injuries.
Keywords: antibiofilm, antimicrobial peptide, collagen, ESKAPE, Klebsiella pneumoniae, multidrug-resistant
bacteria, wound-healing
INTRODUCTION
According to the World Health Organization (WHO), antimicrobial resistance is currently
disseminated worldwide and can affect anyone, regardless of age, health and socio-economic status
(WHO, 2014). Amongst drug-resistant infectious pathogens, which include viruses, parasites,
fungi and bacteria, the latter are of special concern in healthcare facilities, as the most severe
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hospital-acquired infections (HAI) are often associated with
multidrug-resistant (MDR) bacteria belonging to the so-called
“ESKAPE” group: Enterococcus faecium, Staphylococcus aureus,
Klebsiella pneumoniae, Acinetobacter baumannii, Pseudomonas
aeruginosa, and Enterobacter spp. (WHO, 2014). Antibiotic-
resistant HAI are life-threatening and greatly increase the
risks of standard medical procedures, from major surgery,
organ transplantation, or chemotherapy, to management of
complicated skin and soft tissue infections (cSSTI). Actually,
cSSTI like diabetic foot ulcers (DFU), venous ulcers, pressure
ulcers, frequently culminate in hospitalization, where HAI
may exacerbate the severity of the infected wounds (Leong
et al., 2018). Also, cSSTI may develop as HAI, associated
with, e.g., orthopedic or dental implantation (implant-associated
infections, IAI) or use of catheters (catheter-associated infections,
CAI) (VanEpps and Younger, 2016). Consequently, efficient
options for management of cSSTI are urgently needed, especially
because their incidence increases with aging. In fact, cSSTI
are a mounting burden to both patients and healthcare due
to growth of life expectancy: for instance, according to the
European Wound Management Association (EWMA, 2014),
about 2% of the population in developed countries suffers from
chronic wounds, being estimated that 25–50% of hospital beds
are occupied by patients with such non-healing injuries, with
average costs adding up to 2–4% of the total European budget for
healthcare; in the US, the Center for Disease Control estimates
that about 50–70% of the 2 million reported HAI are associated
to implants or catheters, with mortality rates ranging from
<5% for dental implants to >25% for mechanical heart valves
(VanEpps and Younger, 2016).
As efficient options to fight MDR bacteria are being exhausted,
preclinical and clinical development of antimicrobial peptides
(AMPs) has been experiencing a strong impulse (Aminov, 2010;
Gomes et al., 2017; Costa et al., 2019). AMPs have broad-
spectrum antibacterial activity, and low propensity to induce
resistance, hence latest efforts in this area have been focused
on the search for AMPs with potent action, particularly against
MDR Gram-negative bacteria (Ballantine et al., 2019; Mant
et al., 2019; Wang et al., 2019). Findings thereof are quite
encouraging toward devising new options to tackle cSSTI like
DFU, as the most prevalent bacterial species isolated from these
ulcers include, besides the Gram-positive S. aureus, several Gram-
negative species like P. aeruginosa, E. coli, K. pneumonia, and
Proteus mirabilis (Ogba et al., 2019). Also, biofilm forming
bacteria with a major role in cSSTI, including IAI and CAI,
encompass Staphylococcus epidermidis (main species associated
to IAI and CAI), S. aureus (slightly less prevalent than the
previous one, but more aggressive), enterococci and Gram-
negative bacteria like E. coli and Klebsiella spp.; in catheter-
associated urinary tract infections (UTI), E. coli and Candida
yeasts prevail, whereas Gram-positive pathogens are not so
common (VanEpps and Younger, 2016; Li et al., 2019). Still, an
efficient treatment of cSSTI should provide not only antibacterial
protection, but also promote fast tissue regeneration, which
is often deficient in elderly people, especially if bedridden,
or affected by diabetes, chronic venous insufficiency, among
other conditions (Makrantonaki et al., 2017). Although some
AMPs have been reported as having intrinsic skin and soft
tissue regenerative properties, in some cases associated with
collagenesis-inducing effects (Mangoni et al., 2016; Gomes et al.,
2017), most such dual-action AMPs are not potent against Gram-
negative bacteria, and/or their activity has not been investigated
on MDR clinical isolates and/or bacterial biofilms.
In view of the above, we hypothesized that the conjugation of a
collagenesis-inducing, or collagen-boosting peptide (CBP) to an
AMP known to be active against both Gram-positive and Gram-
negative bacteria might produce dual-action peptide chimeras
retaining the properties of their parent CBP and AMP motifs,
hence, with potential interest for the management of cSSTI.
To this end, the CBP chosen was the matrikine-like peptide
KTTKS, also known as “pentapeptide-4” (ahead abbreviated to
PP4) whose palmitoylated form (ahead abbreviated to C16-PP4)
is widely used as a cosmeceutical known as “Matrixyl” (Jones
et al., 2013; Choi et al., 2014; Aldag et al., 2016; Schagen, 2017)
and reported to possess tissue regenerative properties (Tsai et al.,
2007; Park et al., 2017; Krishnamoorthy et al., 2018). As the
AMP motif, we chose a previously de novo designed synthetic
peptide, named 3.1, earlier reported as highly active against both
Gram-positive and Gram-negative bacteria (Kang et al., 2009).
Both CBP and AMP motifs were conjugated in different ways to
produce nine distinct chimeric peptides (Table 1). The in vitro
activity of these peptide chimeras against relevant bacterial
pathogens (both ATCC reference strains and MDR clinical
isolates), as well as their toxicity to human fibroblasts (HFF-1),
antibiofilm properties, and collagenesis-inducing behavior, were
investigated in vitro, and revealed a highly promising peptide
lead, 3.1-PP4, as next described.
MATERIALS AND METHODS
Peptide Synthesis
Peptides were assembled by solid peptide phase synthesis
(SPPS) on an automated Symphony
R©
X synthesizer from
TABLE 1 | Synthetic CBP/AMP conjugates produced by SPPS.
Peptidea Sequenceb MW/Da
3.1 KKLLKWLLKLL 1394.9
C16-3.1 Palmitoyl-KKLLKWLLKLLc 1633.3
PP4 KTTKS 562.7
C16-PP4 Palmitoyl-KTTKS 800.6
PP4-3.1 KTTKSKKLLKWLLKLL 1940.5
C16-PP4-3.1 Palmitoyl-KTTKSKKLLKWLLKLL 2179.0
3.1-PP4 KKLLKWLLKLLKTTKS 1940.5
C16-3.1-PP4 Palmitoyl -KKLLKWLLKLLKTTKS 2179.0
PP4-βala-3.1 KTTKS-β-Ala-KKLLKWLLKLLd 2011.6
aAll peptides were produced as C-terminal amides. bAA residues represented by
the single letter code as defined by the IUPAC-IUBMB guidelines on nomenclature
and symbolism for amino acids and peptides. cPalmitoyl corresponds to the
hexadecanoyl group, introduced by coupling hexadecanoic (i.e., palmitic) acid to
the peptides’ N-terminus. dβ-Ala stands for the non-proteinogenic amino acid
β-alanine (3-aminopropanoic acid).
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Gyros Protein Technologies (Tucson, AZ, United States). The
orthogonal Fmoc/tBu scheme was applied (Benoiton, 2006),
using a Rink amide MBHA resin (100–200 mesh, 0.52 mmol/g,
NovaBiochem) as solid support, which was pre-conditioned
in dimethylformamide (DMF, Sigma-Aldrich, St. Louis, MO,
United States) for 10 min. The Fmoc protecting group was
then removed by treating the resin twice with a solution of
20% piperidine (Sigma-Aldrich, St. Louis, MO, United States)
in DMF for 5 min, thus releasing the resin-bound reactive
amine groups. The C-terminal Fmoc-protected amino acid
(Fmoc-AA-OH, Bachem) was next coupled to the deprotected
resin, which was treated twice for 10 min with a cocktail
solution containing 100 mM of the Fmoc-AA-OH, 100 mM
of the in situ coupling reagent O-(6-chlorobenzotriazol-1-yl)-
N,N,N’,N’-tetramethyluronium hexafluorophosphate (HCTU,
NovaBiochem) and 200 mM N-methylmorpholine (NMM,
Sigma-Aldrich, St. Louis, MO, United States) in DMF. The
Fmoc-protecting group was removed as before, to release the
amino acid (AA) amine group for subsequent coupling of
the next Fmoc-AA-OH. Hence, the peptide chain was grown
in the C→N direction through alternating coupling and
deprotection cycles, performed as above described, until the
full sequence was assembled. For N-palmitoylated peptides
(as, e.g., C16-PP4), after deprotection of the N-terminal AA,
palmitic acid (Sigma-Aldrich, St. Louis, MO, United States) was
coupled by manual synthesis, using an in situ coupling cocktail
solution containing 5 molar equivalents (eq) of palmitic acid,
5 eq of N-ethyl-N,N-diisopropylamine (DIEA, Sigma-Aldrich,
St. Louis, MO, United States), and 10 eq of O-(Benzotriazol-
1-yl)-N,N,N’,N’-tetramethyluronium hexafluorophosphate
(HBTU, NovaBiochem) in DMF. Once fully assembled, the
peptides were released from the resins through a 2 h acidolytic
cleavage reaction using a cocktail solution containing 95%
trifluoroacetic acid (TFA, Sigma-Aldrich, St. Louis, MO,
United States), 2.5% triisopropylsilane (TIS, Sigma-Aldrich,
St. Louis, MO, United States), and 2.5% of deionized water.
The crude peptide thus obtained was purified by a preparative
high-performance liquid chromatography (HPLC), on Hitachi-
Merck LaPrep Sigma system (VWR) equipped with an LP3104
UV detector and an LP1200 pump, employing a reverse-
phase C18 column (250 × 25 mm ID and 5 µm pore size,
Merck) and gradient elution using 0.05% TFA in water as
solvent A and acetonitrile (ACN, Carlo Erba) as solvent B.
The elution method varied according to the specific peptide
and all elutions were completed in 60 min, at a 15 mL/min
flow-rate. Pure peptide fractions were isolated and pooled,
and freeze-dryed to produce the peptide as a low density
white solid that was stored at −20◦C until further use. Peptide
purity was confirmed by analytical HPLC using a Hitachi-
Merck LaChrom Elite system equipped with a quaternary
pump, a thermostated automated sampler, and a diode array
detector; analyses were performed with a reverse-phase C18
column (150 × 4.6 mm ID and 5 µm pore size, Merck) at
a 1 mL/min flow rate using a 1–100% of solvent B (ACN)
in solvent A, for 30 min, with detection at 220 nm. Peptide
structure was confirmed by electrospray ionization-ion trap mass
spectrometry (ESI-IT MS).
Antibacterial Activity
The minimum inhibitory concentration (MIC) of synthetic
peptides was determined using the broth microdilution method
in cation-adjusted Mueller-Hinton broth (MHB2 – Sigma-
Aldrich, St. Louis, MO, United States), according to the
recommendations of the Clinical and Laboratory Standards
Institute (CLSI, 2012), against four reference strains, namely,
P. aeruginosa ATCC 27853, E. coli ATCC 25922, S. aureus ATCC
25923 and Enterococcus faecalis ATCC 29212. MIC values of
peptide 3.1-PP4 were also determined against MDR clinical
isolates of P. aeruginosa (PA002, PA004, Pa3, Pa4), E. coli (Ec1,
Ec2, EC001, EC002, EC003) and K. pneumoniae (KP004, KP007,
KP010). The peptides were tested in the concentration range of
1–1024 µg/mL. The minimum bactericidal concentration (MBC)
was determined as previously reported (Bessa et al., 2018).
Antibiofilm Activity
The ability of peptide 3.1-PP4 to inhibit the biofilm formation
by three P. aeruginosa isolates (PA002, PA004, Pa3) and by three
K. pneumoniae isolates (KP004, KP007 and KP010) was assessed
at concentrations equal to the MIC, 1/2×MIC and 1/4×MIC in
tryptic soy broth – (TSB – Liofilchem s.r.l., Italy) using the crystal
violet assay as reported by Gomes et al. (2014). Two independent
experiments were performed in triplicate.
The efficacy of peptide 3.1-PP4 on 24 h preformed biofilms
of PA002, PA004, KP004, KP007, and KP010 was also evaluated
(Gomes et al., 2014). Briefly, biofilms were grown in TSB from
a starting inoculum of 1 × 106 CFU/mL in 96-well microtiter
plates. After 24 h of incubation at 37◦C, the planktonic cells
were gently removed and the wells were rinsed and filled with
20 × MIC of the peptide. The optical density at 600 nm
(OD600) was measured at time 0 and after incubation for
24 h at 37◦C. The reduction in the biofilm proliferation was
calculated in comparison to the respective non-treated biofilms.
Two independent experiments were performed in triplicate.
Biofilm Metabolic Activity
Twenty four hours biofilms of PA004, KP004, KP007, and KP010
were formed as described above in 96-well microtiter plates and
then treated with 20 × MIC of peptide 3.1-PP4 for further
24 h at 37◦C. The respective control biofilms were equally
formed but in absence of the peptide (only TSB medium was
used). Afterward, the bacterial metabolic activity of biofilms
was quantified after adding 3-(4,5-dimethylthiazole-2-yl)-2,5-
diphenyl tetrazolium bromide (MTT, 0.5 mg/mL – Sigma-
Aldrich, St. Louis, MO, United States) for 3 h at 37◦C in the
dark. DMSO was used to dissolve the formazan crystals formed
and the absorbance at 570 nm was measured. Two independent
experiments were performed in four replicates.
Confocal Laser Scanning Microscopy
Imaging of Biofilms
For confocal laser scanning microscopy (CLSM) imaging,
24 h biofilms of PA004, KP007, and KP010 were formed
in µ-Dish (35 mm, high), ibidi Polymer Coverslips (ibidi
GmbH, Planegg-Martinsried, Germany) as previously described
by Bessa et al. (2018). Biofilms were non-treated – controls
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(only medium was used) or treated with 3.1-PP4 at a
concentration of 20 ×MIC. After 24 h, all biofilms were stained
using the LIVE/DEADTM BacLightTM bacterial viability kit
(Molecular Probes, Thermo Fisher Scientific, MA, United States).
Biofilms were visualized under a laser scanning confocal system
Leica TCS SP5 II (Leica Microsystems, Germany), equipped with
an inverted (i) microscope Leica DMI6000-CS, using a HC PL
APO CS 63x/1.30 Glycerine 21◦C objective and the lasers Diode
405 nm and DPSS561 561 nm, and (ii) the LAS AF software.
Toxicity to Human Fibroblasts
Immortalized human foreskin fibroblasts (HFF-1) were grown
as a monolayer from passage number 8–16. For routine
maintenance, HFF-1 cells were cultured in Dulbecco’s Modified
Eagle Medium (DMEM, from Cell Lines Service) supplemented
with 15% fetal bovine serum (FBS, from CLS) and 1%
antibiotic/antimycotic solution (100 units/mL of penicillin, 100
µg/mL of streptomycin and 0.25 µg/mL of amphotericin B,
from Sigma-Aldrich, St. Louis, MO, United States) at 37◦C in an
humidified atmosphere with 5% CO2. Cells were harvested by
trypsinization [0.25% (w/v) trypsin-EDTA4Na, Sigma-Aldrich,
St. Louis, MO, United States] twice a week.
The cytotoxicity of synthetic peptides to HFF-1 cells was
evaluated using the standard MTT assay. Briefly, cells were
seeded at a density of 8 × 104 cells/well onto 96-well plate
and incubated at 37◦C in a 5% CO2 atmosphere. Cells were
allowed to grow for 48 h, and serially diluted peptide solutions
(0.78–100 µM) were added to the wells. Then, cells were
incubated for 72 h at 37◦C, after which wells were washed once
with phosphate buffered saline (PBS, Sigma-Aldrich, St. Louis,
MO, United States), followed by addition of a 0.45 mg/mL
MTT solution to each well. Crystals were allowed to form
for 1.5 h. Reaction was stopped by rejecting the medium
and addition of dimethylsulfoxide (DMSO, Sigma-Aldrich, St.
Louis, MO, United States). Absorbance was read at 570 nm
(Biotek PowerWave XS).
Collagenesis-Inducing Effects
Collagen production was assessed as described by Remoué
et al. (2013). Briefly, HFF-1 cells were seeded and incubated as
described previously for the cytotoxicity assay. After the 72 h
incubation with peptides, cells were washed with PBS and the
Sirius Red dye in picric acid solution (Sigma-Aldrich, St. Louis,
MO, United States) was applied to each well. Cells were incubated
at 25◦C for 1 h under orbital shaking. Dye was then rejected, and
cells were washed twice with absolute ethanol (AGA). Once the
wells were dry, 1 M aqueous NaOH (Sigma-Aldrich, St. Louis,
MO, United States) was added, and absorbance read at 540 nm
(Biotek PowerWave XS).
Statistical Analysis
The results regarding the biofilm formation, the treatment of
preformed biofilms and the biofilm metabolic activity were
expressed as mean values ± standard deviation. The statistical
significance of differences between controls and experimental
groups was evaluated using Student’s t-test. P < 0.05 were
considered statistically significant.
RESULTS
Peptide Synthesis
All target peptides (Table 1) were successfully obtained in
high purity degrees and presenting ESI-MS data in agreement
with the expected molecular weights (MW), as shown in the
Supplementary Figures S1–S18.
Antibacterial Activity and Cytotoxicity
According to CLSI guidelines for antimicrobial susceptibility
testing, MIC values were determined for all peptides against
ATCC reference strains of two Gram-positive (S. aureus ATCC
25923 and E. faecalis ATCC 29212), and two Gram-negative
(P. aeruginosa ATCC 27853 and E. coli ATCC 25922) bacterial
species, and are shown in Table 2.
At the end of the cytotoxicity assays, the number of viable
cells was never below that of initially plated cells. As such, data
are represented as peptide concentrations causing 50% growth
inhibition (IC50) on HFF-1 cells, rather than as lethal dosis values.
IC50 values thus obtained are also included in Table 2.
As expected, the parent CBP, i.e., the matrikine-like peptide
PP4, was inactive (MIC > 1024 µg/mL) against all bacterial
strains assayed, whereas the parent AMP, peptide 3.1, was highly
active against both Gram-positive and Gram-negative bacteria.
N-palmitoylation of this AMP led to an increase in cytotoxicity
and a significant decrease or even loss of antibacterial activity.
Relevantly, the hybrid constructs PP4-3.1 and 3.1-PP4, where the
parent CBP and AMP motifs were directly linked together in
both possible orientations, displayed potent antibacterial activity,
which is retained or even improved against Gram-negative
bacteria, as compared to that of parent peptide 3.1. Also, while
PP4-3.1 was considerably more toxic to HFF-1 cells than parent
peptide 3.1 (IC50 value of the former is half in comparison to
the latter), on the contrary, its reversed analog 3.1-PP4 was less
cytotoxic than 3.1. Interestingly, N-palmitoylation of any of these
conjugates led again to a considerable increase in cytotoxicity
and to a decrease in antibacterial activity, whereas insertion of a
small flexible linker (β-alanine) between both motifs, as in PP4-β-
Ala-3.1 vs. PP4-3.1, did not significantly alter either antibacterial
activity or toxicity to HFF-1 cells.
Activity of Peptide 3.1-PP4 Against MDR
Gram-Negative Isolates
In view of the above results, peptide conjugate 3.1-PP4
was selected for further investigation of its activity against
MDR isolates of three Gram-negative bacterial species, namely,
P. aeruginosa (four isolates), E. coli (five isolates), and
K. pneumoniae (four isolates), whose antimicrobial resistance
patterns are provided in the Supplementary Table S1. MDR
isolates of K. pneumoniae were included in this analysis given (i)
the high prevalence of K. pneumoniae in HAI (Zheng et al., 2017),
(ii) that K. pneumoniae isolates used are carbanepem-resistant
strains of an Enterobacteriaceae species, meaning that they are
class 1 priority pathogens for the research and development
of new antibiotics according to the WHO (WHO, 2017), and
(iii) K. pneumoniae bacteria are usually better biofilm producers
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TABLE 2 | MIC and IC50 values obtained for the synthetic peptides against four ATCC reference bacterial strains and HFF-1 cells, respectively.
IC50 ± SEM (µM)c
MIC in µg/mL (in µM) on HFF-1 cells
Peptide E. coli P. aeruginosa S. aureus E. faecalis
ATCC 25922 ATCC 27853 ATCC 25923 ATCC 29212
3.1 8 (6) 4 (3) 4b (3) 4–8 (3–6) 50 ± 3
C16-3.1 128 (78.4) 128b (78.4) >1024 (>627) 256b (158) 23.4 ± 0.7
PP4 >1024 (>1820) >1024 (>1820) >1024 (>1820) >1024 (> 1820) >100
C16-PP4 NDa >100
PP4-3.1 4 (2) 4 (1) 8 (4) 16 (8) 25 ± 2
C16-PP4-3.1 32 (15) 64 (29) 64b (29) 64 (29) 4.98 ± 0.08
3.1-PP4 2 (1) 4 (2) 32 (16) 64 (33) 69 ± 5
C16-3.1-PP4 64 (29) 64b (29) 128b (59) 64–128b (30–59) 17.8 ± 0.5
PP4-β-ala-3.1 4 (2) 4 (2) 8 (4) 8 (4) 24 ± 2
aNot Determined, peptide was insoluble in the medium MHB2. bThe MBC was 2 × the MIC; in all the other cases, the MBC was equal to the MIC. cData expressed as
mean ± SEM of two independent experiments (n = 4–8).
than the other Enterobacteriaceae species used, E. coli (Reisner
et al., 2006). MIC values obtained are shown in Table 3, and
confirm peptide’s 3.1-PP4 potent action against Gram-negative
bacteria, including MDR isolates, with a selectivity index (SI), i.e.,
ratio of IC50 values for mammalian vs. bacterial cells, ranging
from ca. 9–69. In fact, for P. aeruginosa and E. coli, MIC
against MDR isolates were in the same range, or below, of
those previously found for ATCC reference strains (Table 2). For
K. pneumoniae, MIC values ranged between 1 and 4 µM, which
is remarkable. Moreover, minimal bactericidal concentrations
(MBC) were also determined, and found to match the MIC in
all cases, which shows that peptide 3.1-PP4 is bactericidal to all
MDR isolates tested.
Antibiofilm Activity of Peptide 3.1-PP4
Activity of an antimicrobial agent against planktonic bacteria may
not correlate to its action against bacterial biofilms, which are
a major cause accounting for the severity and/or chronicity of
infections, known as biofilm-associated infections. In fact, the
formation of biofilms are described as part of the pathogens’
TABLE 3 | MIC values for 3.1-PP4 against MDR isolates of
Gram-negative bacteria.
Species Isolate MIC in µg/mL (in µM)
P. aeruginosa PA002 4 (2)
PA004 2 (1)
Pa3 2 (1)
Pa4 2 (1)
E. coli Ec1 4 (2)
Ec2 2 (1)
EC001 2 (1)
EC002 2 (1)
EC003 1 (0.5)
K. pneumoniae KP010 2 (1)
KP007 8 (4)
KP004 4 (2)
resistance mechanisms; once established, biofilms represent a
stable microbial population that is hidden from the immune
system and shielded from antibiotics (Donlan, 2002; Mottola
et al., 2016; Omar et al., 2017; Chang, 2018). As such, and since
several AMPs have been reported as efficient antibiofilm agents
(Yasir et al., 2018; Haney et al., 2019), we have further investigated
whether peptide 3.1-PP4 would also display antibiofilm activity.
Such activity was assessed in two different stages, (i) in the biofilm
formation and (ii) in 24 h mature biofilms. To this end, biofilms
of MDR isolates of P. aeruginosa and K. pneumoniae were used,
and results were as described further below. MDR E. coli isolates
were not good biofilm producers, therefore, they were not used
in the antibiofilm activity assays. Indeed, that was not surprising
considering the known significantly distinct ability of different
E. coli isolates to form biofilms in vitro (Reisner et al., 2006).
Inhibition of Biofilm Formation
Some of the MDR isolates of P. aeruginosa and K. pneumoniae
were randomly selected to form biofilms in the absence (controls)
and presence (at MIC, 1/2 × MIC and 1/4 × MIC) of the
peptide 3.1-PP4. In this assay, the test compounds were used
at sub-inhibitory concentrations, since if they had been present
at the MIC or higher concentrations, bacteria would be killed
before starting to produce the biofilms. Hence, by using sub-MIC
concentrations, i.e., that are not enough to fully inhibit bacterial
growth, it was possible to assess how could the peptide interfere
with the normal formation of biofilms. The biofilm biomass
formed was next quantitated through the crystal violet assay, and
the results are shown in Figure 1. These results are presented as
absorbance of crystal violet at 595 nm obtained for each strain in
absence (control) and presence of different concentrations (MIC,
1/2 × MIC, and 1/4 × MIC) of the peptide, as this allows for
comparison of the different amounts of biofilm formed by each
distinct bacterial strain in the control condition.
One immediate observation at Figure 1 shows that
P. aeruginosa biofilms have significantly higher biomass
than those formed by K. pneumoniae isolates, indicating
that P. aeruginosa isolates are stronger biofilm producers in
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FIGURE 1 | Biofilm biomass quantitation of biofilms formed in the presence of peptide 3.1-PP4. Biofilms of three MDR P. aeruginosa (PA002, Pa3, and PA004) and
of three MDR K. pneumoniae (KP004, KP007, and KP010) were formed in the presence of the peptide at three different concentrations, MIC, 1/2 × MIC, and
1/4 × MIC. Control biofilms were grown in absence of the peptide. Two independent experiments were performed in triplicate. Error bars represent SD. Statistically
significant differences between biofilms formed in presence of the peptide and respective control biofilms (p < 0.05) are marked with an asterisk (∗).
comparison to those of K. pneumoniae. An absorbance under 0.5
anticipates that no biofilm was formed (Stepanovic et al., 2007),
therefore, as it was expectable, when peptide 3.1-PP4 was present
in a concentration equal to the MIC, no biofilm was actually
produced by the isolates, with the exception of isolate PA002.
Occasionally for some isolates the MIC is different depending
on the medium used (Andrews et al., 2002) and indeed the
medium used in the biofilm formation, TSB, is different from
that used in the MIC determination assay, MHB2. In the case
of isolate PA002, the MIC in TSB is higher than in MHB2, and
thus the concentration of peptide assayed as being the MIC
is in fact a sub-inhibitory concentration. At sub-inhibitory
concentrations, i.e., at 1/2 and 1/4 of the MIC, the peptide does
not significantly inhibit biofilm formation by any of the three
P. aeruginosa isolates. However, for K. pneumoniae isolates, the
peptide is able to reduce the biofilm formed in comparison to the
control biofilm.
Effects on Preformed Biofilms
Biofilms of MDR P. aeruginosa and K. pneumoniae isolates were
allowed to form for 24 h, then exposed to the peptide at 20-fold
its MIC value to ensure that any antibiofilm effects would be
visible, since bacterial biofilms are more difficult to eradicate
than their planktonic counterparts, and then allowed to grow
for another 24 h.
In the case of control biofilms, the second 24 h growth
period occurred in the absence of the peptide. Based on the
apparent higher efficiency of peptide 3.1-PP4 to inhibit the
formation of K. pneumoniae than P. aeruginosa biofilms, only two
MDR isolates of the latter were included in this assay, whereas
three MDR K. pneumoniae were tested. Optical density of the
planktonic phase, as a measure of biofilm proliferation, was
reduced in all peptide-treated biofilms, ranging from 3 to 21%
reduction on P. aeruginosa isolates, and from 34 to 56% reduction
on K. pneumoniae isolates (Table 4).
The influence of the peptide on the metabolic activity of
preformed biofilms of one P. aeruginosa (PA004) and three
K. pneumoniae (KP004, KP007, and KP010) isolates was also
assessed, through a standard MTT assay. Results, expressed as a
percentage of reduction of metabolic activity in peptide-treated
vs. untreated biofilms (Table 4), reinforce that peptide 3.1-PP4
significantly affects the viability of MDR K. pneumonia isolates,
whose metabolic activity can be reduced up to nearly 80% in two
of them (KP004 and KP010), and to 40% in the other.
To gain further insight into the peptide’s effects on the
bacterial biofilms, a Live/Dead staining assay using CLSM
was carried out, where untreated and peptide-treated biofilms
delivered the images depicted in Figure 2. For this analysis,
we selected strains based on their biofilm formation capability,
previously assessed by the crystal violet assay (Figure 1 –
control condition); hence, we opted to use one strong biofilm
producer (P. aeruginosa isolate PA004), one good biofilm
producer (K. pneumoniae isolate KP010), and one weak biofilm
producer (K. pneumoniae isolate KP007). Noteworthy, only
bacterial cells, not biofilm matrix, are stained when the Live/Dead
staining is used, which means that only cells within the
biofilm are observed. A qualitative analysis of images obtained
show that (i) the ratio of red- to green-stained bacterial cells
is consistently higher in peptide-treated compared to their
respective untreated biofilms, and (ii) 3.1-PP4 has highest
impact on the biofilm of isolate KP010, as significant biofilm
disaggregation is observed in this case.
Collagenesis-Inducing Effects
The CBP-AMP conjugates herein addressed include a
collagenesis-inducing motif, the amino acid sequence KTTKS
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TABLE 4 | Effects of peptide 3.1-PP4, at 20 × MIC, on 24 h preformed MDR bacterial biofilms.
MDR isolate OD600 of the planktonic
phase in untreated biofilms
OD600 of the planktonic phase
in peptide-treated biofilms
% reduction in biofilm
proliferation upon treatmenta
% reduction of metabolic activity in
peptide-treated biofilmsb
PA002 0.65 ± 0.03 0.63 ± 0.04 2.8 –
PA004 0.91 ± 0.03 0.71 ± 0.05 21 8.3
KP004 0.63 ± 0.02 0.28 ± 0.00 56 79
KP007 0.56 ± 0.01 0.37 ± 0.03 34 40
KP010 0.64 ± 0.01 0.32 ± 0.02 49 77
aResults are the mean of two independent experiments performed in triplicate. bTwo independent experiments were performed, each in four replicates.
whose N-palmitoylated derivative is the well-known “Palmitoyl
pentapeptide-4” (C16-PP4) that emerged in 2000 under the
commercial name Matrixyl as an active ingredient in skin
rejuvenating cosmetics. Hence, the most promising synthetic
peptide 3.1-PP4 was further tested to establish whether or not
it exhibited collagenesis-inducing effects comparable to those
of C16-PP4. To this end, collagen produced by HFF-1 human
fibroblasts was determined by the previously validated Picrosirius
Red Staining Protocol (Remoué et al., 2013), taking C16-PP4
FIGURE 2 | CLSM after Live/Dead staining of P. aeruginosa and
K. pneumoniae biofilms allowed to grow for 24 h and next grown either in
absence (control) or presence (treated) of peptide 3.1-PP4 at 20 × MIC;
(A) PA004 isolate, (B) KP007 isolate, and (C) KP010 isolate.
as reference CBP. Results from this type of assay are better
interpreted on a comparative basis, as Picrosirius Red staining
may occasionally lead to an overestimation of absolute collagen
production (Coentro et al., 2017). Results are presented in
Figure 3, and expressed as the ratio between collagen produced
and the number of viable cells, as the test peptides had different
cytotoxicity against the HFF-1 cell line.
The assays were performed at concentrations representative
of the MIC values for 3.1-PP4 against MDR isolates of Gram-
negative bacteria. Based on the dose-response curves of both
compounds, we observed that, within the experimental error,
the collagenesis-inducing behavior of peptide 3.1-PP4 was not
statistically different from that of Matrixyl (C16-PP4). In other
words, by replacing the palmitoyl group in Matrixyl with the
amino acid sequence of the antimicrobial peptide 3.1, we were
able to retain the CBP character of Matrixyl, while converting it
into an AMP with potent antibacterial and antibiofilm action on
MDR Gram-negative bacteria.
DISCUSSION
From Fleming’s serendipitous discovery of Penicillin, in 1928, to
the end of the 1980’s, many antibiotics have been developed and
marketed but, in the last four decades, no truly new antibiotic
classes have been disclosed (Fernandes and Martens, 2017; Costa
et al., 2019). In the past 4 years, Teixobactin (Ling et al., 2015)
and Lungdunin (Zipperer et al., 2016), both cyclic peptides of
bacterial origin, were found to have potent action on MDR Gram-
positive bacteria. This brought new hope to the management
of MDR infections, and refueled the interest on AMP-focused
research, which had been cooling down in the first decade of
this century. However, Teixobactin, Lungdunin, or synthetic
derivatives thereof, are ineffective against Gram-negative bacteria
(Ramchuran et al., 2018; Schilling et al., 2019). Hence, seeking for
new agents to fight MDR Gram-negative pathogens remains an
urgent need and an active field of research.
cSSTI refer to practically all types of severe infections, as soft
tissue (SS) includes non-connective tissue like muscles, nerves,
and blood vessels, and connective tissue like tendons, ligaments,
fascia, nerves, fibrous tissues, fat, and synovial membranes;
this leaves out only bone and teeth, the hard tissues in the
human body (Skinner, 2006; Stecco et al., 2015). The highly
hydrated extracellular matrix (ECM) of SS comprises a gel phase
(the so-called ground substance) and a fibrous phase (collagen
and elastin), both of which are mainly produced by fibroblasts
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FIGURE 3 | Collagen production by peptide-treated HFF-1 cells, normalized to the number of viable cells for each peptide concentration assayed. No statistically
significant differences were observed between the tested peptides at any of the concentrations assayed. The “palmitoyl pentapeptide-4,” C16-PP4, also known as
Matrixyl, was taken as the reference CBP.
(Sherman et al., 2015). In view of this, we reasoned that peptide
antibiotics effective for the management of cSSTI must combine
the properties of an AMP with those of a CBP, which we are
pursuing through the synthesis and study of AMP/CBP peptide
hybrids like those herein reported.
One first observation regarding these new peptide hybrids
was the higher cytotoxicity of the palmitoylated constructs
as compared to their non-palmitoylated counterparts.
Palmitoylated conjugates were included in this study, due
to both the reported superiority of C16-PP4 toward PP4 as a
collagenesis inducer (Jones et al., 2013; Choi et al., 2014), and
literature accounts on the increased bioactivity of AMP upon
N-acylation with fatty acids (Chicharro et al., 2001; Chu-Kung
et al., 2004; Etzerodt et al., 2011; Li et al., 2018). Still, the
selectivity of AMP conjugated to fatty acids depends on the size
of the latter, with increased toxicity to mammalian cells being
often observed for conjugates where fatty acid chains are longer
than 14 carbons (Nasompag et al., 2015; Ramachandran et al.,
2017), which might explain our results.
The most relevant observation was that all non-palmitoylated
peptide conjugates, i.e., PP4-3.1, PP4-β-Ala-3.1, and 3.1-PP4
were markedly active against both Gram-positive and Gram-
negative reference bacterial strains, but the latter was the less
cytotoxic of the set, being actually safer to human fibroblasts
that the reference AMP, peptide 3.1. It was interesting to
notice the different behavior of PP4-3.1 as compared to its
reversed analog, 3.1-PP4, an observation that comes in line
with many reports on the influence of peptide orientation in
the antimicrobial properties of peptide-drug conjugates (Aguiar
et al., 2019), peptide hybrids (Cavalli et al., 2010), and peptide-
grafted materials (Li et al., 2015; Barbosa et al., 2019).
As such, and despite being slightly less potent against Gram-
positive bacteria than the other two, peptide 3.1-PP4 was
selected for further investigations on its activity against MDR
isolates of Gram-negative pathogens in both planktonic and
biofilm forms, on which its notable antibacterial efficiency could
be confirmed. In addition, the collagenesis-inducing behavior
of 3.1-PP4 was not statistically different from that of the
reference CBP, peptide C16-PP4 (Matrixyl). This is an important
observation, as C16-PP4 has widely reported superiority toward
PP4 alone as a collagenesis-inducer (Jones et al., 2013; Choi
et al., 2014), whereas peptide 3.1 has never been reported to
have collagen-boosting effects. Notwithstanding, although fully
valid for comparative analyses, the collagenesis-inducing activity
assay based on Syrius Red may lead to an overestimation of
collagen content due (Coentro et al., 2017), hence ongoing
work in our lab is targeting quantitation of total collagen
deposition by more accurate methods, e.g., enzyme-linked
immunosorbent assays (ELISA) (Hosseininia et al., 2016) or
quantitative real-time polymerase chain reaction (RT-q-PCR)
analysis of procollagen gene expression (Yamazaki et al., 2005).
These analyses will include parent unmodified PP4 and 3.1
peptides, as well as their 1:1 mixtures, for a full profiling of
collagenesis-inducing activity.
Taking into account its action on K. pneumoniae alone,
peptide 3.1-PP4 is a novel antimicrobial peptide lead of
undeniable relevance: K. pneumoniae is best known for causing
pneumonia, typically as bronchopneumonia or bronchitis,
with a quite poor prognosis if harboring antibiotic resistance;
but the range of clinical diseases caused by this pathogen is
much wider, including UTI, cholecystitis, diarrhea, respiratory
tract infections, chronic wound infections, osteomyelitis,
meningitis, and sepsis. K. pneumoniae can also act as an
opportunistic pathogen, especially for people having respiratory
dysfunctions such as chronic obstructive pulmonary diseases,
among other debilitating conditions. MDR K. pneumoniae
strains are ubiquitous in healthcare settings, where contact with
contaminated medical devices put patients at a serious risk,
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as sepsis is a real menace once the bacteria enter the bloodstream
(Li et al., 2014).
Considering all the above, a wider and deeper study is
underway in order to draw a clearer picture on the dual-action
potential of new hybrid peptides derived from 3.1 and PP4,
and others inspired on them. Thus, additional sets of peptide
hybrids are being synthesized that cover (i) peptide N-acylation
with fatty acids of different lengths, and (ii) modifications aimed
at modulating the peptides physico-chemical properties toward
improved bioavailability. Moreover, ongoing additional assays
on collagenesis-inducing effects are covering a wider range of
peptide concentrations, as well as quantitative determination
of total collagen deposition levels, where unmodified parent
peptides and their 1:1 mixture are also included. Finally,
investigation of the antimicrobial/collagenesis-inducing effects
of combinations between AMP/CBP hybrid peptides and
conventional antibiotics is being pursued, as such mixtures may
reveal important synergistic effects (Bessa et al., 2018; Hollmann
et al., 2018; Otvos et al., 2018; Zharkova et al., 2019).
CONCLUSION
The present disclosure of hybrid peptide constructs combining
the wide spectrum antimicrobial peptide 3.1 and the collagenesis-
inducing peptide PP4 is unprecedented, and results herein
reported demonstrate the potential that such hybrids enclose for
the future development of new potent antibacterial agents that
are also collagenesis inducers. This is particularly relevant in the
context of cSSTI, especially if associated to MDR Gram-negative
bacteria. In this work, by replacing the palmitoyl group of the
well-known cosmeceutical peptide C16-PP4 (Matrixyl) with the
antimicrobial peptide 3.1, a new peptide was produced with
potent action against Gram-negative bacteria, including MDR
isolates of Enterobacteriaceae, namely E. coli and K. pneumoniae.
These are the two most prevalent species in UTI of the elderly,
and also frequently associated to other cSSTI, and to HAI. The
potent action of 3.1-PP4 against K. pneumoniae was further
confirmed on biofilms of different MDR isolates of this pathogen,
whose establishment, growth, and metabolic activity were clearly
affected in the presence of the peptide. As such, this work
represents a new doorway into the ongoing development of new
dual antimicrobial and CBPs inspired on 3.1-PP4, which will be
challenged against a wider panel of microbial pathogens, and
regarding their full profiling as collagenesis inducers. Results
thereof will be timely reported.
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